Attached files

file filename
10-K - FORM 10-K - K-V Pharmaceutical Cod10k.htm
EX-4.7 - PLEDGE AND SECURITY AGREEMENT - K-V Pharmaceutical Codex47.htm
EX-4.9 - PROMISSORY NOTE - K-V Pharmaceutical Codex49.htm
EX-4.6 - CREDIT AND GUARANTY AGREEMENT - K-V Pharmaceutical Codex46.htm
EX-4.12 - REGISTRATION RIGHTS AGREEMENT - K-V Pharmaceutical Codex412.htm
EX-4.10 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-1 - K-V Pharmaceutical Codex410.htm
EX-4.11 - STOCK PURCHASE WARRANT CERTIFICATE NO. W-2 - K-V Pharmaceutical Codex411.htm
EX-21 - LIST OF SUBSIDIARIES - K-V Pharmaceutical Codex21.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex321.htm
EX-23.2 - CONSENT OF KPMG LLP - K-V Pharmaceutical Codex232.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex311.htm
EX-23.1 - CONSENT OF BDO USA LLP - K-V Pharmaceutical Codex231.htm
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - K-V Pharmaceutical Codex322.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - K-V Pharmaceutical Codex312.htm
EX-10.31 - EMPLOYMENT AGREEMENT BETWEEN COMPANY AND THOMAS S. MCHUGH - K-V Pharmaceutical Codex1031.htm
EX-10.4 - K-V PHARMACEUTICAL COMPANY FIFTH RESTATED PROFIT SHARING PLAN & TRUST AGREEMENT - K-V Pharmaceutical Codex104.htm

Exhibit 4.8

TRANCHE B-1 TERM LOAN NOTE

 

$40,200,000.00

   N-1

November 17, 2010

   New York, New York

FOR VALUE RECEIVED, K-V PHARMACEUTICAL COMPANY, a Delaware corporation (“Borrower”), promises to pay U.S. HEALTHCARE I, L.L.C. (“Payee”) or its registered assigns the principal amount of forty million two hundred thousand dollars ($40,200,000.00) in the installments referred to below.

Borrower also promises to pay interest on the unpaid principal amount hereof, from the date hereof until paid in full, at the rates and at the times which shall be determined in accordance with the provisions of that certain Credit and Guaranty Agreement, dated as of November 17, 2010 (as it may be amended, supplemented or otherwise modified, the “Credit Agreement”; the terms defined therein and not otherwise defined herein being used herein as therein defined), by and among Borrower, certain Subsidiaries of the Borrower, as Guarantors, the Lenders party thereto from time to time, and U.S. HEALTHCARE I, L.L.C. (“U.S. Healthcare”), as Administrative Agent and Collateral Agent.

Borrower shall make scheduled principal payments on this Note as set forth in Section 2.9 of the Credit Agreement.

This Note is one of the “Tranche B-1 Term Loan Notes” in the aggregate principal amount of $60,000,000 and is issued pursuant to and entitled to the benefits of the Credit Agreement, to which reference is hereby made for a more complete statement of the terms and conditions under which the Tranche B-1 Term Loan evidenced hereby was made and is to be repaid.

All payments of principal and interest in respect of this Note shall be made in lawful money of the United States of America in same day funds at the Principal Office of the Administrative Agent or at such other place as shall be designated in writing for such purpose in accordance with the terms of the Credit Agreement. Unless and until an Assignment Agreement effecting the assignment or transfer of the obligations evidenced hereby shall have been accepted by the Administrative Agent and recorded in the Register, Borrower, each Agent and Lenders shall be entitled to deem and treat Payee as the owner and holder of this Note and the obligations evidenced hereby. Payee hereby agrees, by its acceptance hereof, that before disposing of this Note or any part hereof it will make a notation hereon of all principal payments previously made hereunder and of the date to which interest hereon has been paid; provided, that the failure to make a notation of any payment made on this Note shall not limit or otherwise affect the obligations of Borrower hereunder with respect to payments of principal of or interest on this Note.

This Note is subject to mandatory prepayment and to prepayment at the option of Borrower, each as provided in the Credit Agreement.


THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR PURPOSES OF SECTIONS 1271, 1272, 1273 AND 1275 OF THE UNITED STATES INTERNAL REVENUE CODE OF 1986, AS AMENDED. THOMAS S. MCHUGH (WITH AN ADDRESS AT C/O K-V PHARMACEUTICAL COMPANY, ONE CORPORATE WOODS DRIVE, BRIDGETON, MO 63044) WILL PROMPTLY MAKE AVAILABLE TO HOLDERS UPON REQUEST, THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY OF THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF BORROWER AND PAYEE HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.

THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF BORROWER AND PAYEE HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.

IN THE EVENT OF A CONFLICT BETWEEN THIS NOTE AND THE CREDIT AGREEMENT, THE PROVISIONS OF THE CREDIT AGREEMENT WILL GOVERN.

Upon the occurrence of an Event of Default, the unpaid balance of the principal amount of this Note, together with all accrued and unpaid interest thereon, may become, or may be declared to be, due and payable in the manner, upon the conditions and with the effect provided in the Credit Agreement.

The terms of this Note are subject to amendment only in the manner provided in the Credit Agreement.

No reference herein to the Credit Agreement and no provision of this Note or the Credit Agreement shall alter or impair the obligations of Borrower, which are absolute and unconditional, to pay the principal of and interest on this Note at the place, at the respective times, and in the currency herein prescribed.

Borrower promises to pay all costs and expenses, including reasonable attorneys’ fees, all as provided in the Credit Agreement, incurred in the collection and enforcement of this Note. Borrower and any endorsers of this Note hereby consent to renewals and extensions of time at or after the maturity hereof, without notice, and hereby waive diligence, presentment, protest, demand notice of every kind and, to the full extent permitted by law, the right to plead any statute of limitations as a defense to any demand hereunder.

[Signature page follows]

 

2


IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed and delivered by its officer thereunto duly authorized as of the date and at the place first written above.

 

K-V PHARMACEUTICAL COMPANY
  

Name:

Title: